This section of our site provides general information about AOP Orphan. Our Communications Manager will be happy to answer any questions or comments you may have:
Modestas Jocius
AOP Orphan Pharmaceuticals AG
Representative office for the Baltic states
Didzioji st. 25, LT-01128 Vilnius
Lithuania
Tel +370 672 12222
Fax +370 5 2755203
modestas.jocius(at)aoporphan.com
19.03.2020:
Vienna, March 16, 2020 On Wednesday March 11 the World Health Organization (WHO) announced a pandemic in response to the COVID-19 outbreak. This is a serious health situation influencing numerous countries worldwide. We want to...
more about "AOP Orphan Statement on SARS-CoV-2 and COVID-19"
BESREMi® is approved as first-line monotherapy in adults for the treatment of Polycythaemia vera (PV) without symptomatic splenomegaly BESREMi® showed high and durable hematologic response, molecular response and disease...
AOP Orphan Pharmaceuticals AG, the Austrian specialist for rare diseases, will implement ‘Mobile IntelligenceTM (MI)’ - the smart CRM Tool from leading Life-Sciences consultant, IQVIA.
more about "AOP Orphan to implement innovative CRM system in collaboration with IQVIA Austria "
Bioprojet Pharma SAS and AOP Orphan Pharmaceuticals AG (AOP Orphan) entered a distribution agreement for Wakix®The covered territory includes mainly Central and Northern European countriesWakix® is approved for treatment of...
AOP Orphan supports the Christian Doppler Laboratory for Iron Metabolism and Anemia Research at the Medical University of Innsbruck, Austria, opening on January 31st, 2018. To read the full press release in German, please click...
AOP Orphan Pharmaceuticals AG announced today that it has acquired Selisistat, a highly selective SIRT1 inhibitor, which in experimental studies has previously shown potential disease modifying properties in a number of...
05.09.2017:
An interview with Dr Rudolf Widmann, CEO and Dr Christoph Klade, CSO about the current status of Vienna, Austria as a Research & Development base, its specifics, hurdles and chances, which was published recently in...
Cancer Drug News 733
more about "AOP in Press: "New Therapies To Struggle Against Established Hematology""
Long-term maintenance treatment of Polycythemia Vera (PV) patients with Ropeginterferon alfa-2b administered every 4 weeks is feasible, efficacious and well toleratedHome self-administration of individual doses with a pen is well...
AOP Orphan Pharmaceuticals AG (AOP Orphan) today announced that RAPIBLOC® (Rapibloc, 300 mg powder for solution for infusion) will as of June 19th be first commercialized by its distribution partner Amomed Pharma GmbH (Amomed)...
16.05.2017:
An interview with Dr Rudolf Widmann, CEO and Dr Christoph Klade, CSO about AOP Orphan’s commitment to sustainable innovation for the benefit of patients with rare diseases and Austria as a research location was published recently...
Highlights: Ultra-short acting and highly cardio-selective beta blocker Rapibloc® (Landiolol) receives regulatory approval in Europe.Rapibloc® (Landiolol) allows rapid control of heart rate with a straightforward dosing scheme...
As an easy-to-use and highly reliable inhalation powder, the antipsychotic ADASUVE® has revolutionized the treatment of agitation in patients suffering from schizophrenia or bipolar disorder. This was also confirmed by experts...
more about "Innovative antipsychotic ADASUVE® to benefit even more patients"
25.08.2014:
The Austrian pharmaceutical company AOP Orphan, which specialises in rare diseases and innovative therapies, will in future market the antiarrhythmic drug BRINAVESS®, developed by Cardiome Pharma Corp., Canada, in Central Europe....
02.05.2014:
The Austrian pharmaceutical company AOP Orphan is a European pioneer in the field of rare diseases. Industry expert Hans Peter Hasler (58) joined AOP Orphan’s Supervisory Board at the beginning of the year. The Swiss native...
AOP Orphan and Ferrer Internacional are expanding their long-standing partnership to include the marketing of the anti-psychotic drug Adasuve® (Staccato® Loxapine) in Central and Eastern Europe.
more about "Partnership between AOP Orphan and Ferrer: Joint marketing of Adasuve® in CEE"
AOP Orphan announces progress of pan-European phase III trial PROUD-PV to support European Marketing Authorization of AOP2014/P1101, a next-generation, mono-pegylated Interferon alpha 2b.
Modestas Jocius
AOP Orphan Pharmaceuticals AG
Representative office for the Baltic states
Didzioji st. 25, LT-01128 Vilnius
Lithuania
Tel +370 672 12222
Fax +370 5 2755203
modestas.jocius(at)aoporphan.com